A few months ago, Biostar Pharmaceuticals, Inc., a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, made a decision to open a call center in Xianyang to respond to customer queries regarding its health products and also accept new orders.
This business-to-customer sales platform became a reality when the call center commenced operations on December, 10, 2012. Company officials expect that this move will provide an additional boost to the company’s sales efforts going forward.
The B2C call center is currently promoting sales of Biostar products that treat joint pain, kidney ailments, rhinitis, and digestion problems.
"We are confident that the services we are offering through our B2C sales platform will further enhance customer confidence in and loyalty to our products, and will provide an additional boost to the Company's sales efforts going forward,” said Ronghua Wang, CEO and chairman at Biostar.
In order to ensure smooth functioning of the call center, eight operators and six sales agents have been appointed. These personnel have been professionally trained.
Sales personnel at the call center will be saddled with additional responsibilities. In addition to responding to queries and taking orders, staff will also be expected to give customers information regarding drug promotions, make them aware of the new drugs in the market, get feedback regarding the efficacy of the drugs, their side effects, and also help customers to consult with doctors if required.
Apart from this, sales agents will also have to contact medical product distribution agencies throughout the country, sign new agreements with them and also ensure that the old distribution agreements are renewed.
Apparently the call center is a success because according to Wang, since the call center became operational, more than 300 calls are being received daily and sales agents are booking orders in the range of $8,000 - $13,000 every day.
Of course, that is just the beginning of the call center story, for Wang hopes to increase daily sales volumes of health products and is targeting $5 million or thereabouts in revenue in 2013.
Biostar Pharmaceuticals, Inc., announced that it signed a Letter of Intent ("LOI") with The Fourth Military Medical University ("FMMU") to jointly conduct Phases I to III clinical trials for Viacom (News - Alert) Pine II Cream ("Viacom") drug. The LOI has been submitted to China's military authorities for approval.
Want to learn more about the latest in communications and technology? Then be sure to attend ITEXPO Miami 2013, Jan 29- Feb. 1 in Miami, Florida. Stay in touch with everything happening at ITEXPO (News - Alert). Follow us on Twitter.